Napxon Tablet (Delayed Release) 500 mg + 20 mg

Napxon Tablet (Delayed Release) by Ziska Pharmaceuticals Ltd combines 500 mg Naproxen Sodium and 20 mg Esomeprazole Magnesium. This innovative delayed-release tablet effectively manages arthritis pain while reducing gastric ulcer risks. Priced at ৳13.00 per unit, it offers cost-effective therapy for chronic inflammatory conditions.

Designed for patients requiring long-term NSAID therapy, Napxon Tablet (Delayed Release) 500 mg+20 mg features dual-action protection. The immediate-release esomeprazole layer neutralizes stomach acid before the enteric-coated naproxen core dissolves. This mechanism significantly lowers gastrointestinal complications compared to standard NSAIDs.

Key indications include:

• Osteoarthritis management
• Rheumatoid arthritis symptoms
• Ankylosing spondylitis relief
• Prevention of NSAID-induced gastric ulcers

Dosage varies by condition and age. Adults typically take one tablet twice daily. For detailed Naproxen Sodium + Esomeprazole Magnesium regimen guidance, consult healthcare providers. The ৳416.00 pack (4 strips of 8 tablets) ensures month-long supply for regular users.

Special precautions apply for pregnant women and breastfeeding mothers. NSAID components may affect fertility and fetal development. Always store below 30°C, protected from moisture and light. Monitor for potential drug interactions with anticoagulants or blood pressure medications.

Adults: 500 mg naproxen + 20 mg esomeprazole tablet twice daily for arthritis. Adolescents ≥12 years (>50 kg) same dose. Contraindicated in renal impairment (CrCl <30 ml/min). Administer with/without food, but avoid high-fat meals. Use lowest effective dose for shortest duration as per physician guidance.

Immediate release esomeprazole has been included in the tablet formulation to decrease the incidence of gastrointestinal side effects from Naproxen. Naproxen and Esomeprazole tablet has been shown to significantly decrease the occurrence of gastric ulcers and NSAID associated upper gastrointestinal adverse events compared to Naproxen alone. Naproxen: Clinical trial and epidemiological data suggest that use of coxibs and some NSAIDs (particularly at high doses and in long-term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Although data suggest that the use of Naproxen (1000 mg daily) may be associated with a lower risk, some risk cannot be excluded. Oedema, hypertension and cardiac failure have been reported in association with NSAID treatment. The most commonly observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or GI bleeding, sometimes fatal, particularly in older people, may occur. Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn’s disease have been reported following administration. Less frequently, gastritis has been observed.

Pregnancy: Contraindicated in third trimester. Avoid in first/second trimester unless critical. Lactation: Contraindicated. Fertility: NSAIDs may impair female fertility.

Monitor elderly for GI bleeding. Avoid NSAID+corticosteroid combo. Check renal function long-term. Vitamin B12 deficiency possible with prolonged use.

Elderly: Use lowest dose. Renal disease: Contraindicated if CrCl <30. Hepatic impairment: Max 20 mg esomeprazole in severe cases.

Symptoms: Related to Naproxen overdose- Significant Naproxen overdosage may be characterized by lethargy, dizziness, drowsiness, epigastric pain, abdominal discomfort, heartburn, indigestion, nausea, transient alterations in liver function, hypoprothrombinemia, renal dysfunction, metabolic acidosis, apnea, disorientation or vomiting. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression, and coma may occur, but are rare. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs, and may occur following an overdose. It is not known what dose of the drug would be life-threatening.

Related to esomeprazole overdose- The symptoms described in connection with deliberate esomeprazole overdose (limited experience of doses in excess of 240 mg/day) are transient. Single doses of 80 mg esomeprazole were uneventful.

Management: Related to Naproxen- Patients should be managed by symptomatic and supportive care following a NSAID overdose, particularly with respect to GI effects and renal damage. There are no specific antidotes. Hemodialysis does not decrease the plasma concentration of Naproxen because of the high degree of its protein binding. Emesis and/or activated charcoal (60 to 100 g in adults, 1 to 2 g/kg in children) and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms or following a large overdose. Forced diuresis, alkalinization of urine or hemoperfusion may not be useful due to high protein binding.

Related to Esomeprazole- No specific antidote is known. Esomeprazole is extensively plasma protein bound and is therefore not readily dialyzable. As in any case of overdose, treatment should be symptomatic and general supportive measures should be utilised.